Alnylam Pharmaceuticals extends gains after Leerink hikes price target

|About: Alnylam Pharmaceuticals, Inc. (ALNY)|By:, SA News Editor

It's a banner day for sell-side billion dollar biotech bumps, writes theStreet's Adam Feuerstein, citing price target hikes from Leerink and BMO for Celldex Therapeutics (CLDX +11.2%) and Isis Pharmaceuticals (ISIS +7.3%) respectively.

Add Alnylam Pharmaceuticals (ALNY +7.1%) to the party, as Leerink's Marko Kozul ups his price target to $80 from $57.59 citing today's TTR-mediated amyloidosis data.

"Full ALN-TTR-SC (amyloidosis) data incrementally derisk both TTR-SC and ALNY's near term clinical pipeline programs," Kozul notes.